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In RECOVER, a multinational, double-blind, placebo-controlled trial, continuous 24-h transdermal deliv-
ery of rotigotine resulted in signiﬁcant improvements in early-morning motor function and nocturnal
sleep disturbances in subjects with idiopathic Parkinson’s disease (PD). On completion of RECOVER,
subjects were eligible to enter a 1-year, open-label extension in which they received rotigotine
(2–16 mg/24 h) for a 10-month maintenance period. Safety and tolerability were assessed by monitoring
adverse events, changes in vital signs, physical and neurological ﬁndings, ECGs, and clinical laboratory
values. The primary efﬁcacy measure was the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) Part III
(Motor Examination) with the modiﬁed Parkinson’s Disease Sleep Scale (PDSS-2) as a co-primary mea-
sure. Of 84 subjects from RECOVER who enrolled, 79% completed 1 year of open-label treatment. Rotig-
otine was well tolerated; the most common adverse events (AEs; open-label phase) were application site
reactions (ASRs; 24%); somnolence and hallucinations (13% each); nausea and fall (12% each); and dizzi-
ness and dyskinesia (11% each). Most were mild or moderate in intensity and had resolved at the end of
the trial. Twelve subjects (14%) discontinued due to AEs, most commonly ASRs (5 subjects) and peripheral
edema (2 subjects). At end of maintenance, the mean UPDRS Part III score was improved by 5.8 (±9.4)
points relative to open-label baseline and 10.9 (±10.7) points relative to double-blind baseline and the
mean PDSS-2 score by 5.8 (±7.8) points relative to double-blind baseline. Hence, the beneﬁcial effects
of rotigotine transdermal system on motor function and sleep disturbances were sustained for up to
1 year.
 2012 Elsevier GmbH. Open access under CC BY-NC-ND license.n site reaction; BDI-II, Beck
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While the deﬁning feature of Parkinson’s disease (PD) is motor
impairment, leading to symptoms such as tremor, bradykinesia,
and gait disturbances, sleep disorders are also common and signif-
icantly impact the quality of life of PD patients [1–3]. Nonetheless,
only a small number of published trials have prospectively exam-
ined the effects of treatment on sleep in PD [4–9]. One such study
is RECOVER (Randomized Evaluation of the 24-h COVerage:
Efﬁcacy of Rotigotine; NCT00474058 [10]), a multinational, dou-
ble-blind, placebo-controlled trial of the non-ergoline dopamine
agonist (DA), rotigotine (2–16 mg/24 h administered once daily
using a transdermal patch for up to 12 weeks), the ﬁrst large,
80 C. Trenkwalder et al. / Basal Ganglia 2 (2012) 79–85placebo-controlled trial in PD to assess nocturnal sleep disturbance
as a co-primary outcome measure along with motor function. The
RECOVER study demonstrated that 24-h transdermal delivery of
rotigotine to PD patients with early-morning motor dysfunction
resulted in signiﬁcant beneﬁts in control of both early-morning
motor function and nocturnal sleep disturbances over a 12-week
period. While it is known from previous open-label trials
[11–13], that rotigotine results in sustained improvement in motor
function, there have been no studies of rotigotine or, indeed, of any
non-ergoline DA, to include as a co-primary outcome measure, ef-
fects on sleep over an extended period of time. The study described
here (SP915; NCT00519532) is a one-year, open-label extension of
RECOVER, conducted to assess the long-term effects of rotigotine
on motor function, sleep and the non-motor symptoms of PD.Material and methods
Subjects
As subjects were eligible to enter this extension upon comple-
tion of the preceding RECOVER study, its inclusion criteria are
identical to those described previously [10]. Subjects were men
and women (aged P18 years) with PD (Hoehn and Yahr Stage I-
IV) and unsatisfactory control of early-morning motor function as
determined by the investigator. In addition, it was required that
the subject be willing and able to comply with all trial require-
ments and be expected to beneﬁt from long-term treatment with
rotigotine, in the opinion of the investigator. Any subjects who
were experiencing any ongoing serious adverse events (AEs) that
were assessed as related to study medication were not permitted
to enroll in the open-label extension.
This study was conducted in accordance with the International
Conference on Harmonization-Good Clinical Practice require-
ments, the Declaration of Helsinki and the local laws of the coun-
tries involved. The study protocol and amendments were
approved by a national, regional, or Independent Ethics Committee
or Institutional Review Board. All subjects provided written, in-
formed consent before study participation.Study design
At the end of the double-blind trial all subjects had their dose
de-escalated in a blinded fashion in 2 mg/24 h steps over a period
of up to 14 days. Within 2 days of the end of de-escalation those
subjects entering the Phase IIIb, multicenter, multinational, open-
label extension started a dose titration period (lasting up to
8 weeks) in which their dose of transdermal rotigotine increased
in increments of 2 mg/24 h per week from a starting dose of
2 mg/24 h in week 1 until the optimal dose was reached (based
on discussion between patient and investigator and up to a maxi-
mum of 16 mg/24 h). There was no additional wash-out period be-
tween the end of RECOVER and the start of its open-label
extension. The optimal dose was maintained for a 10-month main-
tenance period. Subjects who did not continue on commercially
available rotigotine then had their dose de-escalated over a 14-
day period in 2 mg/24 h increments every other day.
Clinic visits occurred weekly during dose titration; at the start
of the maintenance period; 4 weeks later (to conﬁrm optimal
dose); and at 13-week intervals thereafter. An end-of-treatment
visit occurred at the end of the maintenance period or upon prema-
ture discontinuation with a safety follow-up visit 28 days later. A
subject’s rotigotine dose could be increased or decreased as
required to maintain an optimal dose during the maintenance
period.Permitted concomitant medications were: L-dopa (in combi-
nation with benserazide or carbidopa); MAO-B inhibitors; anti-
cholinergic agents; NMDA antagonists; entacapone; certain
atypical neuroleptics and modaﬁnil. In addition, antiemetics
without central antidopaminergic activity were permitted during
the trial to treat nausea and vomiting.Outcome measures
Safety and tolerability were assessed throughout the study and
up to 30 days after treatment discontinuation by monitoring the
frequency and severity of AEs, and any changes in vital signs, phys-
ical and neurological ﬁndings, ECGs, and clinical laboratory values.
Application and instillation site reactions (MedDRA high-level
term, referred to as application site reactions [ASRs]) are known
to occur with the rotigotine patch and so are of particular interest;
they comprise application site hypersensitivity, pruritus, ery-
thema, reaction, irritation, inﬂammation, rash, eczema, and vesi-
cles. Slight reddening of the skin upon patch removal does not
constitute an ASR.
The primary efﬁcacy outcome measure was the Uniﬁed Parkin-
son’s Disease Rating Scale (UPDRS) Part III (Motor Examination)
[14] with the modiﬁed Parkinson’s Disease Sleep Scale (PDSS-2)
[15] as a co-primary measure. UPDRS Part III was assessed at every
titration visit; at maintenance visits 2, 3, and 4; at the end-of-treat-
ment visit; and the safety follow-up visit, while the subject was in
the ‘‘on’’ state. The self-administered PDSS-2 questionnaire was
completed at all visits during the maintenance period and at end-
of-treatment.
Secondary efﬁcacy outcome measures were the Nocturnal Aki-
nesia, Dystonia, and Cramps Score (NADCS) [2] and number of noc-
turias. Exploratory outcome measures were the short-form
Parkinson’s Disease Questionnaire (PDQ-8) [16]; UPDRS Part II
(Activities of Daily Living) score; Beck Depression Inventory (BDI-
II) [17]; PD Non-Motor Symptom Scale (NMSS) [18]; and an 11-
point Likert Pain Scale. In addition, the UPDRS Part IV was used to
assess complications of therapy–dyskinesias (duration, disability,
pain and presence of early morning dystonia), clinical ﬂuctuations
(off periods) and other complications (anorexia, nausea, vomiting,
insomnia, hypersomnolence or symptomatic orthostasis).Statistical analysis
Efﬁcacy analyses were performed on the full analysis set – all
subjects who received at least one dose of trial medication, had a
valid baseline assessment for the primary and co-primary efﬁcacy
variables, and at least one valid post-baseline measurement during
the titration or maintenance periods. Safety analyses were per-
formed on the safety set (all subjects who received at least one rot-
igotine patch). Descriptive statistics for the sum scores in all
outcome measures were provided as the respective change from
baseline by visit. Because there was no washout period between
studies, meaning that subjects are unlikely to have returned to
an un-medicated state at baseline of the open label extension
study, visit 2 of the double-blind (RECOVER) study was deﬁned
as baseline in reporting efﬁcacy results, except for UPDRS for which
baseline was deﬁned as the ﬁrst titration visit of the open-label
phase; this was because of a difference in the administration of
UPDRS between RECOVER and its open-label extension – UPDRS
was measured in the early morning in RECOVER but could be mea-
sured at any time of the day during the open-label extension. In a
post-hoc analysis, mean change in UPDRS Part III scores from dou-
ble-blind baseline were also calculated. End of maintenance was
deﬁned as the last available post-baseline value until the end of
the maintenance period.
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with subjects considered to be 20%, 25% and 30% responders if, at
the end of maintenance, their UPDRS Part III total scores were im-
proved relative to open-label baseline by P20%, 25%, and 30%,
respectively.Results and discussion
Subjects
Enrolment into SP915 was lower than originally anticipated be-
cause of a change in the manufacturing process of the rotigotine
patches that required them to be refrigerated. This change meant
that not enough rotigotine patches could be supplied within the re-
quired time frame to complete this study. So that subjects already
enrolled had sufﬁcient trial medication to complete the trial
according to the protocol (without switching to the refrigerated
product), further enrollment into SP915 was stopped in April
2008. Hence, of the 246 subjects who completed the RECOVER
study, 84 continued into this open-label extension and, of these,
79% (n = 66) completed one year of treatment. Of these 84 subjects,
61 had been randomized to rotigotine and 23 to placebo in RE-
COVER. Subject disposition and demographics at baseline of the
RECOVER study for the subjects enrolled in SP915 are summarized
in Table 1. Although the mean age of the 84 subjects enrolled in
SP915 was slightly higher (66.3 [10.4] years) and their mean
UPDRS Part III sum score slightly lower (28.1 [13.7]) than that of
the total RECOVER cohort (n = 287; mean age, 64.6 [9.7] years;
mean UPDRS Part II sum score, 30.4 [12.7]) at baseline of RECOVER,
this does not constitute a clinically relevant difference in the SP915
cohort. Rather it reﬂects the enrolment procedure, in that those
subjects who were enrolled ﬁrst into RECOVER were likewise ﬁrst
to be enrolled in its open-label extension.
As shown by the distribution of patients in each UPDRS Part III
sum score category (mean UPDRS Part III sum score of 28.1; Table
1), this was a population with PD severity that ranged from mild to
severe. Indeed, Hoehn and Yahr stage I–IV was an inclusion crite-
rion for the preceding RECOVER study. Subjects received rotigotine
at doses ranging from 2 to 16 mg/24 h for a mean duration of
321 days (range, 42–397 days) in this trial. While 22 subjects en-
tered the maintenance phase at the maximum rotigotine dose level
of 16 mg/24 h, the median dose upon entering the maintenance
phase was 12 mg/24 h. The mean dose over the maintenance phase
was 11.5 (±3.8) mg/24 h (range, 2–16 mg/24 h).Table 1
Demographic and baseline characteristics (safety set, n = 84).
Age (mean [SD]), years 66.3 (10.4)
Gender, n (%)
Male 57 (67.9)
Female 27 (32.1)
L-DOPA, n (%):
Early 10 (11.9)
Advanced 74 (88.1)
BMI (mean [SD]), kg/m2 27.0 (4.2)
UPDRS Part III sum score, mean (SD) 28.1 (13.7)
UPDRS Part III sum score categories, n (%)
0–9 6 (7.1)
10–19 16 (19.0)
20–29 27 (32.1)
30–39 18 (21.4)
P40 16 (19.0)
PDSS-2 sum score, mean (SD) 19.7 (9.7)
Time since ﬁrst diagnosis of PD, mean (SD); yearsa 4.9 (4.5)
Baseline is visit 2 of the RECOVER study except for UPDRS Part III for which baseline
is the ﬁrst titration visit of the open-label extension.
a Time to baseline of the open-label extension.The majority (88%) of subjects enrolled in this study were
taking L-dopa at baseline. All of these remained on combination
therapy throughout the trial while an additional 3 subjects (two
of whom had been randomized to rotigotine and one to placebo
in RECOVER) started L-dopa de novo during the trial (after 148,
156 and 239 days, respectively). A fourth subject (who had been
randomized to rotigotine in RECOVER) started L-dopa during the
safety follow-up period to SP915. The other 6 subjects (7.1%) were
not taking L-dopa at baseline; nor did they take it at any time dur-
ing the study. For the 74 subjects who took L-dopa continuously,
the mean dose of L-dopa remained relatively stable over the course
of the study; indeed, at the end of maintenance, the mean daily
dose of L-dopa (494 mg) was slightly lower than at titration week
1 (538 mg) suggesting that the disease symptoms were being suf-
ﬁciently well managed by the combination of rotigotine and L-
dopa that no further L-dopa dose increases were required.Safety
Overall, 68 subjects (81%) reported 473 AEs; of these 15 sub-
jects (18%) reported 24 AEs that were ongoing from RECOVER.
The most common of the ongoing AEs were nausea (3 subjects
[4%]); ASRS (2 subjects [2%]) and tremor (2 subjects [2%]). Overall,
the most common AEs were ASRs (n = 20; 24%); somnolence
(n = 11; 13%); hallucination (n = 11; 13%); nausea (n = 10; 12%); fall
(n = 10; 12%); dizziness (n = 9; 11%); and dyskinesia (n = 9; 11%), all
of which were consistent with dopaminergic stimulation, the use
of the transdermal patch, and the patient’s comorbidity and age.
There was no correlation between rotigotine dose and AE
incidence. The AE proﬁle was similar to that observed for the
rotigotine-treated subjects in the RECOVER study and in other
short-term trials of rotigotine as well as with other non-ergoline
DAs [19]. The main differences in AE proﬁle between RECOVER
and its open-label extension were for ASRs and nausea. ASRs were
reported by 15% of the rotigotine-treated subjects in RECOVER
compared with 24% of those enrolled in the extension trial. The
somewhat higher incidence seen in the extension trial may be sim-
ply the consequence of its longer duration as well as the fact that
some subjects in the extension had been randomized to placebo
in the preceding double-blind study, and so were receiving rotigo-
tine de novo in SP915. Of the reported AEs, only nausea occurred
with a lower incidence in the extension study than in the
preceding double-blind study (where its incidence among the
rotigotine-treated subjects was 21%) suggesting that nausea may
be a symptom that resolves with continued use.
Of the 473 reported AEs, 94% were mild or moderate in intensity
and 322 (68%; in 68 [81%] subjects) were resolved at the end of the
study. AEs of severe intensity that were reported by more than one
subject were ASRs (in 3 subjects [4%]) and pain in extremity (3 sub-
jects [4%]). Of the 20 subjects who experienced ASRs in this study,
17 (20.2%) were recovered at the end of the study. Twelve subjects
(14%) reported 20 AEs that led to discontinuation, most commonly
ASRs (5 subjects [6%]) and peripheral oedema (2 subjects [2%]).
Overall, 16 subjects (19%) reported 22 serious AEs, none of which
was reported by more than one subject except for femoral neck
fracture (reported by 3 subjects; 4%). Application site vesicles were
the only serious AE that led to discontinuation (by one subject
[1.2%]). Severe AEs leading to discontinuation were application site
inﬂammation, application site vesicles, dyskinesia, obsessive-com-
pulsive disorder, eating disorder, delusions and hallucination (all
occurring in one subject each [1.2%]). In addition, one subject died
of unknown causes during the trial; this was considered by the
investigator to be unlikely to be related to study drug. Otherwise,
the AEs that led to discontinuation were considered related to trial
medication.
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psychiatric disorders. Of these, 44 (reported by 20 subjects
[23.8%] were considered related to study medication and all but
6 events (reported by 3 subjects [3.6%]) were mild or moderate
in severity. The psychiatric disorders included 4 cases of confu-
sional state (in 4 [4.8%] subjects); 22 of hallucination (11 subjects
[13.1%]); 7 of insomnia (7 subjects [8.3%]); 4 of delusional symp-
toms (2 subjects [2.4%]); 2 of depression (2 subjects [2.4%]); and
1 each (in 1 subject [1.2%]) of obsessive-compulsive disorder, eat-
ing disorder, anxiety, agitation, abnormal dreams, abnormal sleep
rapid eye movements, psychotic disorders, dyssomnia, and sleep
disorders. In addition, 3 subjects reported sleep attacks, all of
which were considered possibly related to trial medication. None
of the psychiatric AEs reported were serious and only one (obses-
sive-compulsive disorder) led to study discontinuation. In general,
hematology, clinical chemistry, and urinalysis parameters re-
mained within the normal ranges.
Efﬁcacy
At the end of the 8-week open-label dose titration period, the
mean UPDRS Part III score (±standard deviation [SD]) was improved
relative to open-label baseline (titration visit 1) by 9.9 (±8.2) points
(Fig. 1). This was similar to the improvement relative to double-
blind baseline seen at the end of maintenance of RECOVER for those
subjects randomized to rotigotine in the double-blind phase who
subsequently entered the open-label extension (9.3 ± 7.7 points;
n = 60). The mean UPDRS Part III score remained improved relative
to baseline for the entirety of the 10-month open-labelmaintenance
period (Fig. 1) and, at the end of maintenance, was 5.8 (±9.4) points
lower than at open-label baseline (Table 2) and 10.9 (±10.7) points
lower than at double-blind baseline (when the mean score of the
SP915 subjects combined was 33.2 [±13.4] points). Thus, it appears
that the improvements in motor function in response to rotigotine
treatment that were seen in the RECOVER study were maintainedFig. 1. Mean UPDRS Part III scores over time from the beginning of RECOVER to the en
subsequently enrolled in the open-label extension are shown by double-blind randomiz
combined study population in the open-label phase).for a further year of open-label treatment. Consistent with the
UPDRS Part III scores shown in Fig. 1, responder rates reached their
maximumat titrationweek 7when 67% (n = 18) of all subjects were
classiﬁed as 20% responders. At the end of open-label maintenance,
53% (n = 40) of subjects were still 20% responders and 39% (n = 30)
were still 30% responders.
At the end of the maintenance period of RECOVER, the mean
PDSS-2 score (±SD) of those subjects randomized to receive rotig-
otine who subsequently enrolled in the open-label extension
(n = 60) was improved relative to double-blind baseline by 7.8
(±7.8) points (Fig. 2). At the ﬁrst visit of the maintenance phase
of the open-label study, the change from double-blind baseline
in mean PDSS-2 score for all SP915 subjects combined was 6.4
(±11.6) points. By the second visit of the maintenance period,
4 weeks later, the mean PDSS-2 score had improved by almost 2
more points (to a mean of 8.3 [±8.6] points). The slight decline
in scores observed over the next 13 weeks to maintenance visit
3 may simply be the consequence of patients adjusting to a new
treatment. From maintenance visit 3 the mean PDSS-2 score re-
mained stable and was still improved relative to double-blind
baseline by 5.8 (±7.8) points at the end of maintenance (Table
2; Fig. 2). In addition, the improvements relative to double-blind
baseline that were seen for the rotigotine group at the end of
maintenance of RECOVER (all RECOVER rotigotine subjects;
n = 178) on all 3 PDSS-2 domain scores (disturbed sleep; 2.2
(±3.6) points; motor symptoms at night; 2.0 (±3.2) points; PD
symptoms at night; 1.8 (±2.8) points) were maintained for the
duration of the open-label extension (Table 2). All other measured
efﬁcacy variables–PDQ-8, UPDRS Part II, BDI-II and NMSS total
score (measures of quality of life, mood, nonmotor symptoms,
and pain) also indicate long-term improvements for up to one
year of open-label rotigotine treatment (Table 2). In addition,
improvements were seen on most of the individual domains of
the NMSS, except for perception/hallucinations, attention/memory
and gastrointestinal tract (Table 2). A total of 25 subjects (30.1%)d of maintenance of the open-label extension (mean scores of those subjects who
ation [placebo or rotigotine] during the double-blind [RECOVER] phase and for the
Table 2
Summary of efﬁcacy results, Study SP915 (full analysis set).
Outcome measure Mean (SD) baselinea score Mean (SD) score at
end of maintenanceb
Mean (SD) change from baselinea
score at end of maintenanceb
Primary outcome measures
UPDRS Part III 28.1 (13.7); n = 83 22.0 (13.7); n = 76 5.8 (9.4); n = 76
PDSS-2 total score 19.9 (9.6); n = 83 14.1 (9.4); n = 78 5.8 (7.8); n = 78
PDSS-2 individual domain scores
Disturbed sleep 9.6 (3.9); n = 83 7.2 (3.8); n = 79 2.5 (4.1); n = 79
Motor symptoms at night 5.7 (4.0); n = 83 3.5 (3.6); n = 79 2.2 (3.5); n = 79
PD symptoms at night 4.6 (3.6); n = 83 3.4 (3.6); n = 79 1.3 (3.1); n = 79
Secondary outcome measures
NADCS 3.0 (2.5); n = 83 1.4 (1.6); n = 79 1.5 (2.1); n = 79
Number of nocturias 2.0 (1.5); n = 82 1.6 (1.4); n = 78 0.4 (1.2); n = 78
Other outcome measures
PDQ-8 29.3 (18.0); n = 82 22.5 (16.8); n = 79 6.7 (15.0); n = 78
UPDRS Part II 12.3 (6.1); n = 82 11.1 (6.5); n = 76 1.2 (4.6); n = 76
BDI-II 11.5 (8.5); n = 83 8.4 (7.0); n = 77 3.3 (6.7); n = 77
NMSS 43.4 (39.9); n = 80 32.9 (32.6); n = 77 13.4 (31.2); n = 74
NMSS individual domain scores
Cardiovascular 1.2 (2.3); n = 83 0.9 (1.7); n = 77 0.3 (2.4); n = 77
Sleep/fatigue 11.1 (12.2); n = 81 6.2 (7.6); n = 77 5.8 (10.1); n = 75
Mood/apathyc 7.7 (11.6); n = 83 3.4 (6.9); n = 77 4.6 (10.8); n = 77
Perception/hallucinations 0.7 (1.8); n = 83 0.8 (2.0); n = 77 0.0 (2.0); n = 77
Attention/memory 4.4 (7.4); n = 83 4.9 (7.7); n = 77 0.2 (8.8); n = 77
Gastrointestinal tract 3.5 (4.7); n = 83 4.2 (6.1); n = 77 0.5 (4.2); n = 77
Urinary 6.9 (7.7); n = 82 6.2 (8.5); n = 77 0.9 (6.1); n = 76
Sexual function 3.2 (6.0); n = 83 2.6 (5.9); n = 77 0.6 (5.1); n = 77
Miscellaneous 5.0 (6.3); n = 83 3.7 (5.1); n = 77 1.3 (4.9); n = 77
Likert pain scale 2.6 (2.2); n = 83 1.9 (3.1); n = 79 0.7 (3.0); n = 79
Efﬁcacy results are for the full analysis set.
a Baseline refers to double blind baseline (Visit 2 of the RECOVER study) for all outcomes except for UPDRS (Parts II and III) for which baseline was the ﬁrst titration visit of
the open label extension.
b Last available value from the maintenance period.
c Note that the mood/apathy domain was referred to as the mood/cognition domain in RECOVER.
Fig. 2. Mean change from double-blind baseline in PDSS-2 scores over time from baseline of RECOVER to the end of maintenance of the open-label extension (mean change
scores of those subjects who subsequently enrolled in the open-label extension are shown by double-blind randomization [placebo or rotigotine] during the double-blind
[RECOVER] phase and for the combined study population in the open-label phase).
C. Trenkwalder et al. / Basal Ganglia 2 (2012) 79–85 83spent none of their waking day in the OFF state at baseline of
SP915 (as measured using the UPDRS Part IV item 39) compared
with 21 subjects (25.3%) at the end of maintenance. Likewise,there was little change in the incidence of dyskinesias over the
course of the study as measured using UPDRS Part IV item 32
(‘‘what proportion of the waking day are dyskinesias present?’’):
84 C. Trenkwalder et al. / Basal Ganglia 2 (2012) 79–8562 subjects (74.7%) and 57 subjects (68.7%) reported that they
were not experiencing dyskinesias at baseline and at end of main-
tenance of SP915, respectively.Conclusions
Over the course of this one-year, open-label extension study,
rotigotine, given at an optimal dose ranging from 2 to 16
mg/24 h (mean dose over the maintenance period of 11.5
[±3.8] mg/24 h), was generally well tolerated. AEs were mainly
typical, dose-related dopaminergic effects and were generally mild
or moderate in intensity. Few were serious and most had resolved
by the end of the study. There was a slightly higher incidence of
ASRs in the open-label extension compared with the preceding
double-blind study, but this may reﬂect the longer duration of
the extension study and the fact that subjects randomized to
placebo in RECOVER were receiving rotigotine de novo in Study
SP915.
In addition, rotigotine (added to L-dopa in most cases) led to
long-term improvements in motor function and sleep quality in
subjects with idiopathic PD. Indeed, the improvements that were
attained during the RECOVER trial were sustained over the subse-
quent one-year extension. The small, gradual increase in mean
UPDRS Part III scores over the maintenance period is consistent
with the progressive nature of the disease and is comparable with
what has been observed in other PD trials [20–22]. Nonetheless,
mean UPDRS Part III scores remained improved relative to baseline
for the entirety of the 10-month maintenance period. UPDRS Part
III responder rates dropped slightly over the course of the one-year
study (from 67% at week 7 of the titration period to 53% at the end
of open-label maintenance). This is consistent with the observation
that L-dopa dose remained stable throughout the study and in-
cludes an approximate decline in UPDRS Part III score of approxi-
mately 3 points per year due to the natural progression of the
disease. Moreover, the results are consistent with those of a study
on sustained release ropinirole, that also demonstrated an
improvement in sleep, as measured using the original version of
the PDSS [23,24]. It has been suggested that the persistent sleep
disturbances characteristic of PD are the result of the ‘‘wearing
off’’ of therapeutic beneﬁt associated with commonly used dopa-
minergic therapies, including L-dopa, that have a relatively short
half-life [25]. Hence, the stable improvement in sleep (as measured
by the total and individual domain PDSS-2 scores) seen over a per-
iod of up to 1 year in this study may be the result of the stable plas-
ma levels of rotigotine produced by continuous drug delivery from
the transdermal patch [26–28]. Treatment with rotigotine also led
to stable improvements in quality of life, mood and pain over the
course of this 1-year trial with important implications for patient
well-being.
This study has a number of potential limitations: ﬁrstly, the
results could be biased by the fact that this is an open-label,
unblinded study with no placebo control. Of course, this is an
essential aspect of long-term studies in which it would be unethi-
cal to leave patients untreated. In addition, it must be acknowl-
edged that the low enrolment in this study – the result of
changes in the formulation of the rotigotine patch – limits the con-
clusions that can be drawn. Finally, interpretation of the results
may be confounded by the facts that disease severity in the study
population ranged from mild to severe (mean UPDRS Part III score
of 28.1) and that almost all subjects received concomitant L-dopa
for the duration of the trial. As this was not a de novo trial, large
changes on scores measuring disease symptoms would not be
expected. Nevertheless, this study suggests that rotigotine trans-
dermal system represents a noteworthy addition to the choice of
agents available for the long-term treatment of idiopathic PD.Competing interests
All investigators received grant payments from UCB for enroll-
ing patients into the study. C.T. has received personal compensa-
tion for consulting services from Solvay, UCB, Boehringer
Ingelheim, GlaxoSmithKline Inc., Cephalon, Lundbeck, Vifor
Pharma, and Axxonis Pharma, and has received ﬁnancial support
for research activities from TEVA Pharmaceuticals and Boehringer
Ingelheim. K.R.C. has received personal compensation for activities
with Solvay S.A., GlaxoSmithKline Inc., Ipsen, Britannia, Teva Phar-
maceuticals, and UCB. P.D. and D.H. have no additional conﬂicts of
interest to declare. E.S., J.W., and B.B. are employees of the study
sponsor; J.W. and B.B. receive stock options from this employment.
Authors’ contributions
C.T., J.W., B.B. and K.R.C. were involved in the conception and
design of this study. C.T., B.K., P.D., D.H., and K.R.C. were responsi-
ble for the acquisition of data, in the role of study investigators.
C.T., E.S., J.W. and B.B. conducted data analysis and interpretation.
All authors were involved in drafting or critically revising the arti-
cle for important intellectual content and for the ﬁnal approval of
the published manuscript.
Acknowledgements and funding
The SP915 Study Group is composed of the following study
investigators: Tim Anderson, Van Der Veer Institute for Parkinsons
and Brain Research, Christchurch, New Zealand; Bernard Booth-
man, Bupa Fylde Coast Hospital, Blackpool, UK; Jennifer Fine, Con-
stantiaberg Medi-Clinic, Cape Town, South Africa; Jose Maria
Gómez-Arguelles, MD, Sanatorio Nuestra Señora del Rosario,
Madrid, Spain; Michael William Hayes FRACP, Concord Hospital,
Concord, NSW, Australia; Gábor Jakab, F}ovárosi Önkormányzat
Uzsoki utcai Kórház Neurológiai Osztály, Budapest, Hungary; Jan
Kassubek, Universität Ulm, Ulm, Germany; Jens Carsten Möller,
MD, Philipps-University, Marburg, Germany; Vilho Myllyla, MD,
Oulu University Hospital, Oulu, Finland; Marco Onofrj, MD,
Universita G. D’Annunzio di Chieti-Pescara, Italy; Reinhard Puzich,
Neurologisches Facharztzentrum Berlin, Berlin, Germany; Thomas
Schwerdtfeger, Naumberg, Germany; Malcolm Steiger, The Walton
Centre of Neurology, Neurosurgery, Liverpool, UK; Alexander
Storch, Klinik u. Poliklinik f. Neurologie, Dresden, Germany;
Eduardo Tolosa, MD, Neurology Service, Centro de Investigación
Biomédica en Red sobre Enfermedades Neurodegenerativas
(CIBERNED), Universitat de Barcelona, Spain; Andrzej Tutaj,
Wojewodzki Szpital Specjalistyczny, Olsztyn, Poland; Alberto
Vasquez, Suncoast Neuroscience Associates, Inc., St Petersburg,
FL, USA; Marco Zucconi, MD, Instituto Scientiﬁco H San Raffaele,
Milan, Italy.
In addition, the authors acknowledge the contribution of
Miriam Schmid, Clinical Project Manager, UCB Pharma, Monheim,
Germany, who managed the set-up, global conduct, and reporting
of the trial data and Ging-Ging Li CMPP, Global Publications Man-
ager, Movement & Sleep Disorders, UCB Pharma, Brussels, Belgium
for publication coordination. Under direction of the authors, pro-
fessional medical writing assistance was provided by Aideen
Young, PhD, Evidence Scientiﬁc Solutions, Horsham, UK, and was
contracted by UCB Pharma. This study was wholly funded by
UCB Pharma, Monheim, Germany.
References
[1] Happe S, Schrödl B, Faltl M, Happe S, Schrödl B, Faltl M, Müller C, Auff E,
Zeitlhofer J. Sleep disorders and depression in patients with Parkinson’s
disease. Acta Neurol Scand 2001;104:275–80.
C. Trenkwalder et al. / Basal Ganglia 2 (2012) 79–85 85[2] Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in
Parkinson’s disease. J Neurol 1998;245(Suppl 1):S15–8.
[3] Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders
in patients with Parkinson’s disease. Mov Disord 1998;13:895–9.
[4] Dusek P, Busková J, Ru˚zicka E, Majerová V, Srp A, Jech R, Roth J, Sonka K. Effects
of ropinirole prolonged-release on sleep disturbances and daytime sleepiness
in Parkinson disease. Clin Neuropharmacol 2010;33:186–90.
[5] Högl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep,
periodic leg movements in sleep, and early morning motor function in patients
with Parkinson’s disease. Neuropsychopharmacology 2003;28:1866–70.
[6] Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong
DD, Earl NL. EASE-PD adjunct study investigators. Ropinirole 24-hour
prolonged release: randomized, controlled study in advanced Parkinson
disease. Neurology 2007;68:1108–15.
[7] Rektorova I, Balaz M, Svatova J, Zarubova K, Honig I, Dostal V, Sedlackova S,
Nestrasil I, Mastik J, Bares M, Veliskova J, Dusek L. Effects of ropinirole on
nonmotor symptoms of Parkinson disease: a prospective multicenter study.
Clin Neuropharmacol 2008;31:261–6.
[8] Romigi A, Stanzione P, Marciani MG, Izzi F, Placidi F, Cervellino A,
Giacomini P, Brusa L, Grossi K, Pierantozzi M. Effect of cabergoline added
to levodopa treatment on sleep-wake cycle in idiopathic Parkinson’s
disease: an open label 24-hour polysomnographic study. J Neural Transm
2006;113:1909–13.
[9] Wolters EC, Tesselaar HJ. International (NL-UK) double-blind study of Sinemet
CR and standard Sinemet (25/100) in 170 patients with ﬂuctuating Parkinson’s
disease. J Neurol 1996;243:235–40.
[10] Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P,
Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E,
PoeweW, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, Recover Study
Group. Rotigotine effects on early morning motor function and sleep in
Parkinson’s Disease: a double-blind, randomized, placebo-controlled study.
Mov Disord 2011;26:90–9.
[11] LeWitt PA, Boroojerdi B, Poewe W. On behalf of the SP516 and SP715 study
groups. Long-term treatment of advanced Parkinson’s disease with
rotigotine. Movement disorder society – 14th international congress of
Parkinson’s disease and movement disorder. Mov Disord 2010;25(Suppl.
2):S299–300.
[12] Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WHL, Giladi N, Boroojerdi B.
Long-term safety and efﬁcacy of transdermal rotigotine in advanced
Parkinson’s disease. American academy of neurology 2009–61st annual
meeting. Neurology 2009;72(Suppl. 3):A321.
[13] Watts R, Boroojerdi B, Jankovic J. Open-Label extension trial assessing the
effects of long-term treatment with rotigotine in subjects with early-stage,
idiopathic Parkinson’s disease: results from up to 7 years. Movement disorder
society – 14th international congress of Parkinson’s disease and movement
disorder on behalf of the SP702 study group. Mov Disord 2010;25(Suppl
2):S310–1.[14] Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martinez-Sarriés J,
Bermejo F. Uniﬁed Parkinson’s disease rating scale characteristics and
structure The Cooperative Multicentric Group. Mov Disord 1994;9:76–83.
[15] Trenkwalder C, Kohnen R, Högl B, Metta V, Sixel-Döring F, Frauscher B,
Hülsmann J, Martinez-Martin P, Chaudhuri KR. Parkinson’s disease sleep
scale—validation of the revised version PDSS-2. Mov Disord 2011;26:644–52.
[16] Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development,
validation and application of a Parkinson’s disease quality of life questionnaire
and its associated measures. J Neurol 1998;245(Suppl. 1):S10–4.
[17] Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ. Reliability and
validity of the Beck depression inventory in patients with Parkinson’s disease.
Mov Disord 2006;21:668–72.
[18] Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR,
Carod-Artal FJ, Prakash R, Esselink RA, Falup-Pecurariu C, Gallardo M, Mir P,
Naidu Y, Nicoletti A, Sethi K, Tsuboi Y, van Hilten JJ, Visser M, Zappia M,
Chaudhuri KR. International study on the psychometric attributes of the non-
motor symptoms scale in Parkinson disease. Neurology 2009;73:1584–91.
[19] Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with
pramipexole and ropinirole in patients with Parkinson’s disease: a meta-
analysis. Drug Safety 2003;26:439–44.
[20] Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W,
Melamed E, Poewe W, Stocchi F, Tolosa E. A double-blind, delayed-start trial of
rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268–78.
[21] Hauser RA, Rascol O, Korczyn AD, Stoessl AJ, Watts RL, Poewe W, De Deyn PP,
Lang AE. Ten-year follow-up of Parkinson’s disease patients randomized to
initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409–17.
[22] Maetzler W, Liepelt I, Berg D. Progression of Parkinson’s disease in the clinical
phase: potential markers. Lancet Neurol 2009;8:1158–71.
[23] EASE-PD Adjunct Study Investigators, Pahwa R, Stacy MA, Factor SA, Lyons KE,
Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL. Ropinirole 24-hour
prolonged release: randomized, controlled study in advanced Parkinson
disease. Neurology 2007;68:1108–15.
[24] Chaudhuri KR, Martinez-Martin P, Rolfe KA, Cooper J, Rockett CB, Giorgi L,
Ondo WG. Improvements in nocturnal symptoms with ropinirole prolonged
release in patients with advanced Parkinson’s disease. Eur J Neurol
2012;19:105–13.
[25] Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and
management of Parkinson’s disease. CMAJ 2003;168:293–301.
[26] Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized,
blind, controlled trial of transdermal rotigotine in early Parkinson disease.
Neurology 2007;68:272–6.
[27] Boroojerdi B, Wolff HM, Braun M, Scheller DK. Rotigotine transdermal patch
for the treatment of Parkinson’s disease and restless legs syndrome. Drugs
Today (Barc) 2010;46:483–505.
[28] Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of
Parkinson’s disease. Expert Opin Pharmacother 2009;10:677–91.
